This month’s investment candidate is Trovagene (TROV), which has a key technology that offers a tremendous improvement in cancer monitoring and detection.The company’s patent-protected urine-based DNA and RNA tests monitor cancer treatment more effectively than current imaging, tissue biopsy and blood tests. Beyond cancer, Trovagene’s tests are also able to identify a wide range of health risks including fetal down syndrome, infectious diseases and transplant acceptance.
